secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001104659-24-029638
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics terminates $25M equity purchase agreement with Lincoln Park Capital
--------------------------------------------------------------------------------

- Terminated Purchase Agreement with Lincoln Park Capital Fund effective March 1, 2024.
- Only 12,500 shares were sold under the agreement, generating ~$33,000 in proceeds.
- Company projects financial runway through Q4 2025; no immediate capital need.
- No early termination penalties; 1.8M commitment shares previously issued to LPC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924029638/0001104659-24-029638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924029638/tm247674d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer